Cytek Biosciences, Inc. CTKB Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $44.14M+6.5% | $62.14M+8.1% | $52.29M+1.5% | $45.6M-2.2% | $41.46M-7.6% | ||
| $22.88M+7.4% | $29.26M+22.8% | $24.74M+10.0% | $21.74M+2.6% | $21.3M-2.5% | ||
| $21.25M+5.4% | $32.89M-2.3% | $27.55M-5.0% | $23.87M-6.2% | $20.16M-12.4% | ||
| 48.2%-0.5pp | 52.9%-5.6pp | 52.7%-3.6pp | 52.3%-2.2pp | 48.6%-2.7pp | ||
| $9.6M-1.2% | $8.96M-7.8% | $8.96M-9.4% | $8.83M-11.7% | $9.73M-0.7% | ||
| $11.65M-6.9% | $13.13M+10.6% | $11.67M-6.1% | $12.13M-1.1% | $12.51M-0.3% | ||
| $18.47M+43.2% | $16.39M+80.7% | $16.12M+47.3% | $13.53M+15.7% | $12.9M+13.1% | ||
| $39.72M+13.1% | $38.48M+25.5% | $36.74M+10.5% | $34.49M+1.6% | $35.13M+4.1% | ||
| $39.72M+13.1% | $38.48M+25.5% | $36.74M+10.5% | $34.49M+1.6% | $35.13M+4.1% | ||
| -$18.46M-23.3% | -$5.59M— | -$9.19M-116% | -$10.62M-24.6% | -$14.98M-39.5% | ||
| -41.8%-5.7pp | -9%— | -17.6%-9.3pp | -23.3%-5.0pp | -36.1%-12.2pp | ||
| $262K-10.0% | —— | $494K+315% | $414K+209% | $291K-34.0% | ||
| $787K+54.9% | $580K-36.5% | $573K-60.0% | $555K-60.8% | $508K-62.6% | ||
| $1.09M-70.6% | $1.56M-78.7% | $1.42M-67.7% | $3.85M+187% | $3.71M+113% | ||
| $1.49M+998% | $40.05M+5,789% | -$2.29M-192% | -$1.19M-137% | $136K+105% | ||
| -$18.87M-65.5% | -$44.08M— | -$5.48M-682% | -$5.58M+46.5% | -$11.4M-84.8% | ||
| -42.7%-15.2pp | -70.9%— | -10.5%-12.3pp | -12.2%+10.1pp | -27.5%-13.8pp | ||
| -$0.15-66.7% | -$0.34— | -$0.04-500% | -$0.04+50.0% | -$0.09-80.0% | ||
| -$0.15-66.7% | -$0.34— | -$0.04-500% | -$0.04+50.0% | -$0.09-80.0% | ||
| -$0.15-66.7% | -$0.34— | -$0.04-500% | -$0.04+50.0% | -$0.09-80.0% | ||
| 128.7M+0.3% | 127.7M-2.2% | 127.5M-3.9% | 126.9M-3.4% | 128.3M-2.0% | ||
| 128.7M+0.3% | 127.7M-2.2% | 127.5M-2.6% | 126.9M-3.4% | 128.3M-2.0% | ||
| -$0.15-66.7% | -$0.34— | -$0.04-500% | -$0.04+50.0% | -$0.09-80.0% | ||
| -$0.15-66.7% | -$0.34— | -$0.04-500% | -$0.04+50.0% | -$0.09-80.0% | ||
| -$18.74M-55.8% | -$42.66M— | -$4.62M-473% | -$5.01M+44.8% | -$12.03M-86.5% | ||
| $328K+159% | $1.38M— | $741K+634% | $603K-56.1% | -$560K-130% | ||
| $565K-83.8% | $258K-47.5% | $1.34M-56.5% | $3.71M+6,185% | $3.49M+324% | ||
| $44.14M+6.5% | $62.14M+8.1% | $52.29M+1.5% | $45.6M-2.2% | $41.46M-7.6% | ||
| -$18.46M-23.3% | -$5.59M— | -$9.19M-116% | -$10.62M-24.6% | -$14.98M-39.5% | ||
| -$16.6M-26.7% | -$3.7M— | -$7.27M-203% | -$8.73M-30.0% | -$13.1M-45.0% | ||
| -$16.6M-26.7% | -$3.7M— | -$7.27M-203% | -$8.73M-30.0% | -$13.1M-45.0% | ||
| -37.6%-6.0pp | -6%— | -13.9%-9.3pp | -19.2%-4.7pp | -31.6%-11.5pp | ||
| -$18.46M-23.3% | -$5.59M— | -$9.19M-116% | -$10.62M-24.6% | -$14.98M-39.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cytek Biosciences, Inc.'s revenue?
- Cytek Biosciences, Inc. (CTKB) generated $204.2M in revenue over the trailing twelve months, up 3.6% year over year.
- Is Cytek Biosciences, Inc. profitable?
- Cytek Biosciences, Inc. is not currently profitable: it reported a net loss of $74.0M over the trailing twelve months, a -36.2% net margin.
- What are Cytek Biosciences, Inc.'s profit margins?
- Gross margin is 51.7% and operating margin is -21.5%, with a -36.2% net margin.
- What is Cytek Biosciences, Inc.'s earnings per share?
- Cytek Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-0.57.
- Where does Cytek Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
